Conference Calls, Philanthropic Activities, Clinical Trial Data, and Regulatory Approvals - Research Report on Celgene, UnitedHealth, Biogen Idec, WellPoint, and Medtronic
NEW YORK, October 4, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Inc. (NYSE: UNH), Biogen Idec Inc. (NASDAQ: BIIB), WellPoint, Inc. (NYSE: WLP), and Medtronic, Inc. (NYSE: MDT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Celgene Corporation Research Report
On October 1, 2013, Celgene Corporation (Celgene) announced that it will host a conference call and a live audio webcast on October 24, 2013, at 9:00 a.m. ET to discuss the Company's Q3 2013 financial and operational results. Celgene stated that the webcast will be available at its website. In addition, the Company will also host a webcast of an investor event at the American College of Rheumatology (ACR) meeting on October 27, 2013 at 6:30 a.m. PT (9:30 p.m. ET). According to Celgene, its management team and clinical investigators will discuss the data presentations at the ACR meeting. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7f47_CELG]
--
UnitedHealth Group Inc. Research Report
On September 27, 2013, UnitedHealth Group Inc. (UnitedHealth Group) reported that its company UnitedHealthcare Community Plan of Tennessee is allocating $1 million in grant funding to increase the housing options available for Tennesseans who suffer from mental illness. According to the Company, UnitedHealthcare Community Plan of Tennessee along with project partners will identify housing developments across the state to receive grant funding and UnitedHealth care will provide $400,000 in grant funding in 2013 and $600,000 in 2014 for developments that provide safe, affordable, quality, and appropriate housing for people living with mental illness. The Full Research Report on UnitedHealth Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/73e5_UNH]
--
Biogen Idec Inc. Research Report
On October 1, 2013, Biogen Idec Inc. (Biogen Idec) announced new data analyses from year one of the two-year, pivotal, Phase 3 ADVANCE study of PLEGRIDY (peginterferon beta-1a). According to the Company, clinical and MRI data from the study demonstrated reduction in relapses, disability progression, and the number of multiple sclerosis (MS) lesions when compared to placebo and further support the clinical efficacy profile of PLEGRIDY. Professor Peter Calabresi, MD, Director, The Johns Hopkins Multiple Sclerosis Center, said, "If approved, PLEGRIDY could become a valuable addition to the interferon class of multiple sclerosis therapies. The combination of efficacy demonstrated across key disease measures and a less frequent dosing schedule has the potential to offer an important therapeutic option for people living with MS." According to Biogen Idec, the two-year Phase 3 ADVANCE clinical trial is a global, multi-center, randomized, double-blind, parallel-group, placebo-controlled study designed to evaluate the efficacy and safety of PLEGRIDY in 1,516 patients with relapsing-remitting MS. The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b95b_BIIB]
--
WellPoint, Inc. Research Report
On October 1, 2013, WellPoint, Inc. (WellPoint) announced that most of WellPoint's 2014 affiliated Medicare drug plans and medical plans with drug coverage will help members save money on their prescription medications through the use of a preferred pharmacy network. According to the Company, its preferred pharmacy network, which comprises of Kroger, Rite Aid, and Walmart pharmacies and their affiliates, is part of all WellPoint's affiliated Part D standalone Prescription Drug Plans (PDPs) and most of its affiliate Medicare Advantage Prescription Drug Plans (MAPD). The Company informed that members may use any of the Company's retail network pharmacies, and will receive savings of around $5 to $8 per copay on most drugs (depending on plan type and drug tier) for using preferred network pharmacies. Further, all standalone PDP plans and a few MAPD plans will feature preferred generics for a $1 copayment. WellPoint stated that its affiliates will staff booths at stores during Medicare's Annual Election Period (October 15, 2013 to December 7, 2013) to speak about PDP and MDP plans which are applicable from January 1, 2014. The Full Research Report on WellPoint, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/64cd_WLP]
--
Medtronic, Inc. Research Report
On September 27, 2013, Medtronic, Inc. (Medtronic) announced that the US Food and Drug Administration (FDA) has approved MiniMed 530G with Enlite, a breakthrough, first-generation artificial pancreas system with Threshold Suspend automation for people with diabetes. According to the Company, Medtronic's system is the first in the United States that can automatically stop insulin delivery when sensor glucose values reach a preset level and when the patient doesn't respond to the Threshold Suspend alarm. The Company added that it will conduct a post-approval study on the MiniMed 530g system by including children of ages two and older. Medtronic informed that it will engage in direct patient follow up and will make certain manufacturing accommodation as a condition of approval. Medtronic said that it will begin ramping up production immediately to prepare for a launch of the MiniMed 530G in the next several weeks.[.]The Full Research Report on Medtronic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/bc94_MDT]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
Share this article